Tirzepatide: a novel, once-weekly dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes
The Muscle, Performance & Body Composition Blueprint helps you understand where each peptide fits, and how to avoid mismatching goals and expectations
The Phase 3 program includes multiple trials examining various indications and patient populations
L-carnitine group (after operation)(L-carnitine were given after operation) and L-carnitine + perhexiline maleate (before operation) group
Since its initial characterization by the Sikiric group at the University of Zagreb in the 1990s, BPC-157 has accumulated an extensive body of preclinical evidence spanning gastrointestinal healing, musculoskeletal repair, neurological protection, and systemic anti-inflammatory activity
A GLP1 prescription could indicate: Well-controlled type 2 diabetes Severe obesity under active treatment Metabolic dysfunction associated steatohepatitis (MASH) Obstructive sleep apnea Elevated cardiovascular risk Chronic kidney disease Clinically, those are very different scenarios with very different mortality implications
